The evidence of safety and efficacy from clinical trials supports the feasibility of selectively targeting FTH1 in cancer therapy, opening up new avenues for treatment strategies for KRAS-mutant pancreatic cancer. This evidence concerns the gene KRAS and familial pancreatic carcinoma.